The current research hypothesized that inhibition of AURKA may be beneficial to the treatment of DLBCL by CHOP, and our objective was to confirm whether siAURKA enhanced the sensitivity of DLBCL to CHOP therapy and the molecular mechanism of AURKA. The gene discussed is AURKA; the disease is diffuse large B-cell lymphoma.